ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

E. Thunnissen,B.I. Lissenberg-Witte,M.M. van den Heuvel, K. Monkhorst,B.G. Skov, J.B. Sørensen,A. Mellemgaard,A.M.C. Dingemans, E.J.M. Speel,A.J. de Langen, S.M.S. Hashemi,I. Bahce,M.A. van der Drift, M.G. Looijen-Salamon,J. Gosney,P.E. Postmus, S.M.S. Samii, F Duplaquet, B. Weynand,X. Durando

Lung Cancer（2019）

引用 10|浏览68

暂无评分

摘要

•Discordant ALK immunohistochemistry positive (IHC) FISH negative NSCLC occurs at low frequency.•Not all locally performed ALK IHC and FISH test were centrally confirmed.•Prognosis of concordant ALK IHC and FISH positive NSCLC is similar as literature.•Prognosis of validated discordant ALK IHC positive FISH negative NSCLC is significantly lower.•In NSCLC a positive ALK IHC screentest should be followed by ALK FISH.

查看译文

关键词

non-small cell lung cancer,alk,immunohistochemistry,fluorescence in situ hybridisation,treatment,prognosis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要